Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | CLL treatment: statistical analysis in predictive medicine

Kevin Coombes • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Cyclophosphamide Fludarabine Rituximab

Kevin Coombes, PhD, Ohio State University, Columbus, OH, discusses identifying biological subsets of chronic lymphocytic leukemia (CLL) patients that are likely to respond to fludarabine, cyclophosphamide, rituximab (FCR) treatment. Dr Coombes elaborates on the statistical techniques and models used to predict which groups would respond best to treatment. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Kevin Coombes

3:20
Implications of CytoGPS
Kevin Coombes • 22 Sep 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals